Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 135 • 2017 Pediatric Rheumatology Symposium
Epigenetic Profiling Of Juvenile Idiopathic Arthritis (JIA) Synovial Fluid Monocytes Points Towards a Role For Monocytes In Bone Damage
Janneke Peeters¹, Arjan Boltjes^2,3, Stephin Vervoort⁴, Paul Coffer¹, Bas Vastert^2,5, Femke van Wijk^2,3, Michal Mokry³, Teun de Vries^6,7 and Jorg van Loosdregt³, ¹Center for Molecular Medicine and Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, ²Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Division of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Peter MacCallum Cancer Centre, Melbourne, Australia, ⁵Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Department of Oral Cell Biology and Functional Anatomy, Academic Centre for Dentistry Amsterdam, Amsterdam, Netherlands, ⁷Department of Periodontology, Academic Centre for Dentistry Amsterdam, Amsterdam, Netherlands
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a multifactorial autoimmune disease characterized by the accumulation of various immune cells, including monocytes, in the joint synovial fluid…
Abstract Number: 64 • 2017 Pediatric Rheumatology Symposium
Evaluating Levels of Activity and Health-Related Quality of Life in a Pilot Cohort of Youth Athletes with Juvenile Idiopathic Arthritis
Tommy Gerschman¹, Jordan Raugust², Julia Brooks³, Nicole Johnson¹, Nadia Luca⁴, Rebeka Stevenson¹, Heinrike Schmeling⁵, Paivi Miettunen¹ and Susanne Benseler⁴, ¹Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ²Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada, ³Pediatrics, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁵University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Children with JIA are increasingly being encouraged to be physically active and are participating in organized and competitive sports as youth athletes. These youth…
Abstract Number: 22 • 2017 Pediatric Rheumatology Symposium
Patient perception of barriers to taking medication in Juvenile Idiopathic Arthritis
Gabriela Guefen¹, Kirsten Jenkins², Lori Ponder², Kelly A. Rouster-Stevens^2,3, Patricia Vega-Fernandez^2,3, Elaine S Ramsay^2,3, Sheila Angeles-Han^2,3 and Sampath Prahalad^2,3,4, ¹College of Arts and Sciences, Emory University, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁴Human Genetics, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Treatments include disease modifying anti-rheumatic drugs, commonly methotrexate (MTX), biologics including Etanercept…
Abstract Number: 114 • 2017 Pediatric Rheumatology Symposium
Clinical Features and Treatment Outcomes in Down’s Arthropathy
Jordan T. Jones¹ and Leena Danawala², ¹Rheumatology Division, Children's Mercy Kansas City, Kansas City, MO, ²University of Missouri-Kansas City School of Medicine, Kansas City, MO
Background/Purpose: Crude prevalence estimates indicate Down’s Arthropathy (DA) is 3-8 times more common than juvenile idiopathic arthritis (JIA), however, DA is still largely under recognized…
Abstract Number: 23 • 2017 Pediatric Rheumatology Symposium
Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies
Kelly Wise¹, Dustin Lewis², Bethanne Thomas², Karla Jones³, Stephanie Lemle², Darby MacDonald², Fatima Barbar-Smiley², Vidya Sivaraman² and Cagri Yildirim-Toruner³, ¹Pharmacy/Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Biologic therapies have become a standard of care for many pediatric rheumatic diseases such as juvenile idiopathic arthritis (JIA) and periodic fever syndromes. Biologics,…
Abstract Number: 52 • 2017 Pediatric Rheumatology Symposium
How Young People with Juvenile Idiopathic Arthritis and Their Caregivers Weigh the Risks of the Disease and its Treatment: A Mixed-Methods Study
Daniel B. Horton^1,2, Jomaira Salas³, Aleksandra Wec⁴, Timothy Beukelman^5,6, Alexis Boneparth¹, Ky Haverkamp⁷, Melanie Kohlheim⁸, Melissa Mannion⁵, Nandini Moorthy¹, Sarah Ringold⁹ and Marsha Rosenthal², ¹Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, ³Department of Sociology, Rutgers, the State University of New Jersey, New Brunswick, NJ, ⁴Rutgers, the State University of New Jersey, New Brunswick, NJ, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Family Medicine, University of Washington School of Medicine, Seattle, WA, ⁸Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ⁹Seattle Children's Hospital, Seattle, WA
Background/Purpose: Prior research has examined factors important to clinicians in deciding whether to withdraw therapy for inactive JIA, but little is known about the perspectives…
Abstract Number: 148 • 2017 Pediatric Rheumatology Symposium
Oral Microbial Profile in Juvenile Idiopathic Arthritis
Sriharsha Grevich^1,2, Peggy Lee³, Jeffrey McLean³, Brian Leroux³, Sarah Ringold^1,2, Kyle Hager⁴, Mitchell Brittnacher⁴, Hillary Hayden⁴, Samuel Miller⁴ and Anne Stevens^1,2,5, ¹University of Washington, Department of Pediatrics, Seattle, WA, ²Seattle Children's Hospital, Seattle, WA, ³University of Washington, School of Dentistry, Seattle, WA, ⁴University of Washington, Department of Microbiology, Seattle, WA, ⁵Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: Microbial communities in the mouth have been associated with the chronic inflammation of periodontitis and rheumatoid arthritis (RA), and there is higher prevalence of…
Abstract Number: 139 • 2017 Pediatric Rheumatology Symposium
Dysregulation of miRNA in mononuclear cells of patients with enthesitis related arthritis
Amita Aggarwal¹ and Sushma Singh², ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Enthesitis related arthritis (ERA) is the most common category of JIA in Asia. Identifying dysregulated microRNA may help in understanding the pathogenesis of ERA.…
Abstract Number: 13 • 2017 Pediatric Rheumatology Symposium
Prevalence of Celiac Antibodies and IgA deficiency in Juvenile Idiopathic Arthritis
Angela Taneja¹, Sampath Prahalad², Aimee O. Hersh³, Lori Ponder⁴, Lai Hin Kimi Chan⁵, Kelly A. Rouster-Stevens⁶, Anne E Tebo⁷, Subramanian Kugathasan⁸ and John F. Bohnsack⁹, ¹Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Pediatrics, Emory Children's Center, Atlanta, GA, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁵Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁶Pediatric Rheumatology, Emory Children's Center, Atlanta, GA, ⁷University of Utah, Salt Lake City, UT, ⁸Gastroenterology, Emory University School of Medicine, Atlanta, GA, ⁹Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic arthritis of childhood. The prevalence of autoimmunity is higher in JIA cases and relatives.…
Abstract Number: 387 • 2016 ACR/ARHP Annual Meeting
Rituximab Should be Considered in Rheumatoid Factor Negative Poly-Articular Juvenile Idiopathic Arthritis
Sunil Sampath^1,2, Liza J. McCann³, Michael W. Beresford^3,4, Eileen Baildam³, Jamie C Sergeant^1,5, Wendy Thomson², Helen Foster⁶, Sharon Douglas², Taunton Southwood⁷, Kimme L. Hyrich¹ and Biologics for Children with Rheumatic Diseases (BCRD) study Group¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ³Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁵NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁶Paediatric Rheumatology, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁷School of Immunity and Infection,Institute of Clinical Sciences,University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Selective peripheral B-cell depletion by rituximab (RTX) is a relatively recent advance in rheumatic diseases. RTX is an approved treatment in RA. Although very…
Abstract Number: 1289 • 2016 ACR/ARHP Annual Meeting
Comparison of Clinical Parameters and PET/MRI in Juvenile Idiopathic Arthritis
Kathleen Jo Corbin¹, Emily von Scheven¹, Youngho Seo², Spencer Behr² and John MacKenzie³, ¹Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, ²Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ³Section of Pediatric Radiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA
Background/Purpose: Positron emission tomography (PET) can be used to identify inflammation using 18F-fluorodeoxyglucose (18F-FDG). 18F-FDG uptake correlates with clinical and laboratory markers of disease activity…
Abstract Number: 388 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Two to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicolino Ruperto², Anasuya Hazra³, Ronnie Wang⁴, Charles Mebus⁴, Christine Alvey⁴, Manisha Lamba⁴, Sriram Krishnaswami⁴, Thomas C Stock³, Umberto Conte⁵, Min Wang⁵, Nikolay Tzaribachev⁶, Ivan Foeldvari⁷, Gerd Horneff⁸, Daniel Kingsbury⁹, Elena Koskova¹⁰, Elzbieta Smolewska¹¹, Richard K Vehe¹², Zbigniew Zuber¹³, Daniel J Lovell¹ and Alberto Martini², ¹Pediatric Rheumatology Collaborative Study Group, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Istituto Giannina Gaslini, Genoa, Italy, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pediatric Rheumatology Research Institute, Bad Bramstedt, Bad Bramstedt, Germany, ⁷Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁸Asklepios Klinik, Sankt Augustin, Germany, ⁹Randall Children's Hospital, Portland, OR, ¹⁰National Institute of Rheumatic Diseases, Piestany, Piestany, Slovakia, ¹¹Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Lodz, Poland, ¹²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN, ¹³St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor that is being investigated for juvenile idiopathic arthritis (JIA). Here, we report the pharmacokinetics (PK), safety, and…
Abstract Number: 1517 • 2016 ACR/ARHP Annual Meeting
Does Inflammatory Arthritis Really Improve during Pregnancy? a Systematic Review and Meta-Analysis
Hannah Jethwa¹, Suzanne Lam², Colette Smith³ and Ian Giles⁴, ¹General Medicine, Wexham Park Hospital, London, United Kingdom, ²Croyden University Hospital, London, United Kingdom, ³Statistics, Royal Free Hospital Foundation Trust, London, United Kingdom, ⁴Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Disease activity is considered to improve in approximately 75% of patients with rheumatoid arthritis (RA) during pregnancy. This figure, however, is derived from…
Abstract Number: 392 • 2016 ACR/ARHP Annual Meeting
Safety and Clinical Response of Weekly Adalimumab in the Treatment of Juvenile Idiopathic Arthritis, Pediatric Chronic Uveitis and Other Childhood Rheumatic Diseases
Colleen K. Correll¹, Danielle R. Bullock¹, Rachel Cafferty¹ and Richard K Vehe², ¹Pediatrics, University of Minnesota, Minneapolis, MN, ²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN
Background/Purpose: Every other week adalimumab is used to treat juvenile idiopathic arthritis (JIA) and other pediatric rheumatic diseases. It is common for pediatric rheumatologists to…
Abstract Number: 2038 • 2016 ACR/ARHP Annual Meeting
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis
C. April Bingham¹, Jesse Pratt², Cagri Yildirim-Toruner³, Ronald Laxer⁴, Beth Gottlieb⁵, Jennifer E. Weiss⁶, Tzielan Lee⁷, Sheetal S. Vora⁸, Jon M. Burnham⁹, Julia Harris¹⁰, Judyann C. Olson¹¹, Murray Passo¹², Michelle Batthish¹³, Michael Shishov¹⁴, Kerry Ferraro¹⁵, Deborah M. Levy¹⁶, Christine O'Brien¹⁷, Kristi Whitney-Mahoney¹⁷, Nancy Griffin¹⁸, Anne Paul¹⁹ and Esi Morgan²⁰, ¹Penn State Health Children's Hospital, Hershey, PA, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁴Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Pediatrics, Cohen Children's Medical Center, Lake Success, NY, ⁶Hackensack Univ Med Ctr, Hackensack, NJ, ⁷Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁸Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁹Pediatric Rheumatology, Children's Hospital Philadelphia, Philadelphia, PA, ¹⁰Children's Mercy Kansas City, Kansas City, MO, ¹¹Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹²Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁴Pediatric Rheumatology, Phoenix Children's Hospital, Phoenix, AZ, ¹⁵Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁷The Hospital for Sick Children, Toronto, ON, Canada, ¹⁸James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁹Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a growing multi-center network organized on a learning health system model designed to improve outcomes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].